Glucose monitors cut HbA1c but not a kilo of weight

Continuous glucose monitors have moved well beyond insulin-dependent diabetes and are now marketed to almost anyone curious about their metabolism. The evidence base, though, was built mostly in people on intensive insulin regimens, where the case for minute-by-minute data is obvious. Whether the devices help adults with type 2 diabetes managed on tablets or simpler insulin schedules was much less settled, particularly for outcomes beyond the standard three-month HbA1c blood test. This review set out to answer that question across the full set of glycaemic measures.

The researchers searched the literature from inception to February 2026 for randomised controlled trials of real-time or intermittently scanned continuous glucose monitoring in adults with type 2 diabetes on non-intensive insulin regimens or non-insulin therapies. They pooled results for HbA1c, mean glucose, time in range, time above range, time below range, body mass index and patient-reported outcomes using random-effects models. Risk of bias was assessed with the Cochrane tool and the overall certainty of the evidence was graded formally. Twenty-five trials met the criteria.

Monitoring reduced HbA1c by 0.34 percentage points and mean glucose by 13.97 mg/dL. Time above range fell by 6.75% while time in range rose by 7.85%, so the gain came largely from trimming high readings. There was no significant change in body mass index, which moved only 0.16 kg/m2, and no significant change in time below range, meaning hypoglycaemia was neither helped nor worsened. Benefits tended to be larger in people not treated with insulin at all. Patient-reported outcomes varied between trials but pointed towards better treatment satisfaction and a better monitoring experience. Certainty was rated moderate across outcomes.

This extends a benefit previously demonstrated mainly in intensively insulin-treated patients to a much larger group managed more simply, and it does so with moderate certainty rather than the thin evidence that existed before. The pattern is coherent: the devices reduce time spent high without pushing people low. It also quietly deflates one popular claim, since weight did not change. Open questions include how long the improvement persists once the novelty of seeing your own curves fades, whether the effect holds outside trial conditions, and whether any of this translates into fewer long-term complications.

For someone with type 2 diabetes managed without intensive insulin, this is reason to think a monitor can shave a meaningful if modest amount off HbA1c, mostly by reducing high excursions. It is not a weight-loss device by this evidence, and it did not reduce low readings either. One of the authors is affiliated with a device manufacturer, which is worth holding in mind when reading any glucose monitoring literature. And none of these trials tested people without diabetes, so the popular use of monitors as a general wellness gadget sits outside what was studied here.